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Introduction: Malignant pleural mesothelioma (MPM) is an aggres-
sive malignancy that most often presents at an advanced, incurable
stage. After the failure of standard first-line cisplatin/antifolate chemo-
therapy, there is no accepted treatment. The vascular endothelial growth
factor pathway may be a relevant therapeutic target in MPM.
Methods: This open-labeled phase II trial evaluated single-agent
sunitinib, an inhibitor of multiple receptor tyrosine kinases including the
vascular endothelial growth factor receptors, given at 50 mg daily orally
for 4 weeks followed by a 2-week rest, in patients with advancedMPM.
Two cohorts were studied: cohort 1, in which patients had previously
received cisplatin-based chemotherapy, and cohort 2, consisting of
previously untreated patients. A two-stage design was used for both
cohorts; the primary outcome was objective response rate as determined
by the RECIST criteria modified for MPM. Secondary outcomes
included rates and duration of disease control, progression-free survival
and overall survival, and safety and tolerability.
Results: A total of 35 eligible patients were enrolled (17 to cohort 1
and 18 to cohort 2). Neither cohort met the criteria for continuing to the
second stage of accrual; only one objective response, confirmed by
independent review, was observed in a previously untreated patient.
Median progression-free and overall survivals were 2.8 and 8.3 months
in cohort 1, and 2.7 and 6.7 months in cohort 2, respectively. Observed
toxicity was within that expected for sunitinib.
Conclusions: Sunitinib, similar to other angiogenesis inhibitors, has
limited activity in MPM. Future trials of angiogenesis inhibitors
given as single agents in unselected patients with MPM are not
warranted.
Key Words: Angiogenesis inhibitor, Mesothelioma, Systemic ther-
apy, Phase II.
(J Thorac Oncol. 2011;6: 1950–1954)
Malignant pleural mesothelioma (MPM) is an uncommonbut highly lethal cancer. After the failure of therapy
with a cisplatin/antifolate combination,1,2 there is no standard
treatment.
Higher levels of vascular endothelial growth factor
(VEGF) are negatively prognostic in MPM.3 Mesothelioma
cells express both VEGF ligands and receptors, suggesting an
autocrine growth loop.4,5
Sunitinib inhibits multiple receptor tyrosine kinases,
including VEGF receptors 1 to 3. Given the potential that
angiogenesis inhibition might be of therapeutic benefit in
MPM, the NCIC Clinical Trials Group undertook this phase
II study.
METHODS
This multicenter trial had two cohorts. Cohort 1 in-
cluded patients who had received 3 prior lines of cytotoxic
chemotherapy, one of which was platinum based. Cohort 2
enrolled chemotherapy-naive patients. Patients were aged 18
years or older and Eastern Cooperative Oncology Group
performance status 0 to 2, had incurable, proven MPM (any
histology), and radiologically measurable disease.
This study was approved by the research ethics boards
of the participating institutions. All patients provided written
informed consent. The trial was conducted in accordance
with Good Clinical Practice guidelines.
Sunitinib, provided by the Cancer Therapy Evaluation
Program of the National Cancer Institute (Bethesda, MD),
was administered 50 mg orally once daily for 28 days,
followed by a 2-week break (1 cycle  6 weeks), with up to
two dose reductions (37.5 mg or 25 mg) for toxicity. In the
absence of unacceptable toxicity or patient request, sunitinib
was continued until disease progression.
Toxicity was graded using the Common Terminology
Criteria for Adverse Events version 3.0 (Bethesda, MD).
Response was assessed by investigators every cycle using
the modification of RECIST for mesothelioma6; at the
completion of the trial, an independent radiology review
was performed.
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The primary end point was objective response rate. A
two-stage design7 was used. For cohort 1, the null hypothesis
was a response rate of 10% versus the alternate hypothesis of
30%, whereas for cohort 2, the values were 15% versus 35%,
respectively; for both, the significance levels were   0.10
and   0.10. For cohort 1, if 2 objective responses were
observed in 16 patients, 10 additional patients would be
accrued, and the treatment deemed of interest for further
study if 5 responses were observed. For cohort 2, if 3
objective responses were observed in 17 patients, an addi-
tional 15 would be accrued, and the treatment deemed of
interest if 8 objective responses were observed.
RESULTS
Patients
Between April 2007 and June 2009, 39 patients were
enrolled (Table 1). One patient was never treated, and three
were found to have no measurable disease on independent
radiology review, leaving 17 eligible patients on cohort 1 and
18 on cohort 2.
Treatment Delivery, Toxicity, and Adverse
Events
The median number of cycles of therapy in both cohorts
was 3. Drug delivery was lower in the previously treated
patients. Fatigue, gastrointestinal complaints, and hand-foot
syndrome were the most common adverse events and the
most common reasons for dose delays and interruptions.
Hematological toxicity was mild, with only one grade 4 event
(asymptomatic thrombocytopenia) (Tables 2–4).
Efficacy
Neither cohort proceeded to stage II. No objective
responses were reported among the previously treated pa-
tients. Eleven had stable disease, for a median duration of 6
months (range: 2.3–12.7 months). The independent review
confirmed these results, with a median duration of disease
stabilization of 5.3 months.
One partial response (duration: 3 months) was observed
among the previously untreated patients; there were 10 with
stable disease for a median of 4.5 months (range: 2.5–12.7
months). The independent review confirmed the partial re-
sponse and determined that 14 patients had stable disease for
a median duration of 3.8 months (range: 1.1–9.0 months).
Figure 1 depicts the waterfall plots for all patients.
The median progression-free survival (PFS) and overall
survival (OS) for the previously untreated patients were 2.7
and 6.7 months, respectively. Median PFS and OS for the
previously treated cohort were 2.8 and 8.3 months (Figures 2
and 3).
DISCUSSION
Despite preclinical evidence suggesting it may be a
relevant target, angiogenesis inhibitors, for example,
sorafenib,9 have not demonstrated significant single-agent
activity in MPM. In a randomized phase II trial, the addition
of bevacizumab to cisplatin/gemcitabine did not improve
survival.3 Another trial of second-line sunitinib in MPM has
been reported in abstract form.10 Objective responses were
observed in 10%, with a median OS of 6.7 months; the
investigators felt that sunitinib had “modest” activity in this
setting. In the current trial of sunitinib, only one partial
response was observed, and while a majority demonstrated
stable disease, this observation may simply reflect the vari-
able natural history of MPM. The median PFS in both cohorts
was less than 3 months, similar to that observed with other
TABLE 1. Patient Characteristics
Characteristics
Cohort 1
(Previously
Treated)
Cohort 2
(Previously
Untreated)
Eligible patients 17 18
Male 14 15
Median age (range) 65 (48–78) 70 (54–79)
ECOG performance status
0 2 5
1 14 13
2 1 0
Number of prior cytotoxic
regimens
0 0 18
1 11 0
2 5 0
3a 1 0
Histology
Epithelioid 10 10
Sarcomatoid 1 4
Biphasic 1 1
Not otherwise specified 5 3
EORTC good prognosis
class8
13 13
a One patient on cohort 1 had received a prior EGFR inhibitor.
ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor
receptor; EORTC, European Organization for Research and Treatment of Cancer.
TABLE 2. Drug Delivery
Median Number
of Cycles (Range)
Planned Dose
Intensity
Actual Dose
Intensity (Median)
% Patients Receiving
>90% of Planned
Dose Intensity
Patients with Dose
Reduction/Off due
to Toxicity
Cohort 1 3 (1–13) 233.3 mg/wk 174 mg/wk 29% 3/2a
Cohort 2 3 (1–9) 233.3 mg/wk 231 mg/wk 78% 9/2b
a Reasons off therapy: multiple grade 1/2 toxicities.
b Reasons off therapy: one each grade 4 thromboembolic event and grade 3 bronchopulmonary hemorrhage.
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targeted agents in both first- and second-line settings (e.g.,
sorafenib9 and erlotinib11). By comparison, in a phase III
study of pemetrexed versus best supportive care in previously
I183  (Radiology Reviewed)
(n =  34 evaluable patients)
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FIGURE 1. Waterfall plot of responses. Note: one patient is
not included, as developed disease progression (brain metas-
tases) and did not have target lesions reimaged.
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FIGURE 2. Overall survival.
TABLE 3. Reported, Related Nonhematological Adverse
Events Occurring At Least Once of At Least Grade 2 in Severity
Number of Patients with NCI
CTCAE (v 3.0) Grade
Cohort 1
(n  17)
Cohort 2
(n  18)
2 3 4 2 3 4
Cardiac general
Hypertension 1 1 2 1
LV systolic dysfunction 1
Constitutional
Fatigue 7 5 8 1
Dermatologic
Hand-foot 2 1
Rash 2
Gastrointestinal
Anorexia 4 1 4
Constipation 1 2
Diarrhea 3 1 1
Esophagitis/heartburn 1 1
Mucositis 5 3
Nausea 4 2
Taste alteration 5 2
Vomiting 2 1
Hemorrhage
Bronchopulmonary 1
Epistaxis 1
Infection
Infection (normal ANC) 1 1
Lymphatics
Edema: trunk/genital 1
Neurological
Dizziness 1
Pain
Abdomen 1
Chest 1
Headache 1
Muscle 2
Vascular
Thrombosis/embolism 1 1
Adverse events considered at least “possibly” related to sunitinib in the opinion
of the investigator. Blank cells indicate no patient experienced the listed
event.
LV, left ventricular.
TABLE 4. Hematological Toxicity
Cohort 1 (n  17) Cohort 2 (n  18)
Median Nadir (Range)
Worst CTC Grade
(No. of Patients)
Median Nadir (range)
Worst CTC Grade
(No. of Patients)
2 3 4 2 3 4
Leukocytes (109/L) 3.8 (2.6–8.9) 3 3.7 (2.2–17.0) 5
Granulocytes (109/L) 2.2 (1.0–7.4) 3 2.25 (1.0–11.9) 4
Hemoglobin (g/L) 103 (83–149) 8 115 (71–140) 4 1
Platelets (109/L) 195 (23–544) 1 1 212 (57–697) 1
Toxicity graded according to NCI CTCAE version 3.0. Blank cells indicate no patient experienced the listed event.
CTCAE, Common Terminology Criteria for Adverse Events.
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treated MPM, pemetrexed led to objective responses in 18%
and a median PFS of 3.6 months.12
Further study of sunitinib (or any angiogenesis inhibi-
tor) as a single agent in unselected patients with MPM is
likely not warranted. The fact that occasional dramatic ob-
jective responses have been observed suggests that there may
be a subgroup that could benefit from these agents. In the
randomized trial adding bevacizumab or placebo to cisplatin/
gemcitabine, improved outcomes with bevacizumab were
observed in patients with VEGF levels below the median
value.3 An ongoing randomized trial of cisplatin-pemetrexed
with or without bevacizumab (NCT 00651456) intends to
further evaluate the relationship between serum VEGF levels
and outcomes.
This study had brisk accrual despite the rarity of MPM
and the fact that this is generally a disease of older men who
often have comorbid illnesses that could preclude enrolment
to a clinical trial. The previously treated cohort, in particular,
was rapidly completed, suggesting a significant unmet clini-
cal need. This cohort had a median OS of 8 months, greater
than that observed in the previously untreated cohort. Others
have also observed a longer OS in previously treated patients
compared with the same agent in the first-line setting,9 but
this is likely the result of patient selection rather than drug
efficacy. Interestingly, in addition to the current trial, other
trials of targeted agents9,11 have reported a median OS in their
previously untreated patients lower than the 12 months ex-
pected with platinum-pemetrexed.1 Those enrolled to a clin-
ical trial are likely suitable for standard chemotherapy, the
majority of patients enrolled to both cohorts were classified as
“good prognosis” by the criteria derived by the European
Organization for Research and Treatment of Cancer,8 but in
this study only 3 of the 17 previously untreated patients
received subsequent systemic therapy. The reasons for this
are not known, and although some might have refused offered
therapy, there may be a risk that exposing untreated patients
to an ineffective experimental therapy impairs the subsequent
delivery of standard treatment. Consideration should be given
to performing studies of novel single agents in MPM only in
those patients who have previously received a platinum-
antifolate combination, while evaluating a new agent in
conjunction with the standard chemotherapy backbone in
previously untreated patients.
Determination of response in MPMmay be problematic
in those with only pleural rind. A modification of RECIST6 is
increasingly used in trials of MPM. The independent review
performed by thoracic radiologists familiar with these criteria
revealed only minor discrepancies in time to disease progres-
sion. Nevertheless, this apparent concordance between the
investigators and the independent radiologists was the result
of numerous data queries arising from monitoring, despite the
fact that a tutorial about the modified RECIST criteria was
made available to all investigators at the initiation of the trial.
Others have similarly noticed the importance of educating
investigators regarding the use of these criteria to ensure
accurate response assessment.13 In future trials, consideration
should be given to a standardized central radiology review,
particularly if response or PFS is a primary end point.
For those who have thin, nonmeasurable pleural rind as
their sole disease, alternate methods of determining response
are needed. Serum soluble mesothelin-related peptide may be
useful in monitoring response,14 as may fluorodeoxyglucose-
positron emission tomography or positron emission tomog-
raphy/computed tomography, using combinations of tumor
volume and metabolic activity such as the “total glycolytic
volume.”15 On-treatment changes in these measurements
have been found to correlate with radiologic response and to
predict survival, and total glycolytic volume values could be
calculated in some patients without radiologically measurable
pleural rind.15 For response determination in these patients,
either or both of metabolic imaging and soluble mesothelin
levels could be combined along with subjective impression of
disease change on standard computed tomography imaging.
The rarity of MPM requires the prudent conduct of trials
to maximize the number of different agents, which can be
studied in limited patients. There have been multiple trials of
angiogenesis inhibitors, all of which have demonstrated similar,
disappointing results. Greater coordination among investigators
would improve efficiency and minimize the number of patients
exposed to ultimately ineffective therapies.
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APPENDIX
A study coordinated by the Clinical Trials Group of the
NCIC. Participating investigators were as follows:
Ottawa Hospital Cancer Centre, Ottawa, Ontario: S.A. Lau-
rie, N.M. Reaume, and G. Nicholas.
Cross Cancer Institute, Edmonton, Alberta: Q. Chu, A.A. Joy,
and A.J. Reiman.
British Columbia Cancer Agency, Vancouver, British Colum-
bia: J.J. Laskin, B.L. Melosky, and N. Murray.
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FIGURE 3. Progression-free survival.
Journal of Thoracic Oncology • Volume 6, Number 11, November 2011 Sunitinib in Advanced Malignant Pleural Mesothelioma
Copyright © 2011 by the International Association for the Study of Lung Cancer 1953
Fraser Valley Cancer Centre, Surrey, British Columbia: T.
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